User:Mr. Ibrahem/Omalizumab
| File:Omalizumab syringe (DermNet NZ xolair-syringe-01).jpg Omalizumab syringe | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IgE Fc region |
| Clinical data | |
| Pronunciation | oh-ma-liz'-oom-ab |
| Trade names | Xolair |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603031 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 26 days |
| Chemical and physical data | |
| Formula | C6450H9916N1714O2023S38 |
| Molar mass | 145058.53 g·mol−1 |
  (what is this?) (verify) | |
Omalizumab, sold under the brand name Xolair, is a medication used to treat asthma, nasal polyps, and urticaria.[6][7] It is used when the cause is allergic and other treatments are not sufficient.[6] It is given by injection.[6]
Common side effects include headache, pain at the site of injection, itching, and abdominal pain.[6] Other side effects may include anaphylaxis, cancer, and heart disease.[7] Following use in a small number of pregnant women there is no evidence of harm to the baby.[8] It is a monoclonal antibody which binds to and inactivates immunoglobulin E (IgE).[6]
Omalizumab was approved for medical use in the United States in 2003 and Europe in 2005.[7][6] In the United Kingdom 150 mg cost the NHS about £260 as of 2021.[9] This amount in the United States costs about 1,200 USD.[10]
References[edit]
- ^ "Archive copy" (PDF). Archived (PDF) from the original on 2021-06-13. Retrieved 2021-07-15.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ "Archive copy" (PDF). Archived (PDF) from the original on 2021-08-28. Retrieved 2021-07-15.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ "Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines". Novartis (Press release). 28 August 2014. Archived from the original on 13 June 2021. Retrieved 12 June 2021 – via PR Newswire.
- ^ "Xolair 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 18 August 2020. Archived from the original on 13 June 2021. Retrieved 12 June 2021.
- ^ "Xolair- omalizumab injection, solution Xolair PFS- omalizumab injection, solution". DailyMed. 11 May 2020. Archived from the original on 28 November 2020. Retrieved 6 December 2020.
- ^ a b c d e f g h i "Xolair EPAR". European Medicines Agency (EMA). Archived from the original on 13 June 2021. Retrieved 12 June 2021.
- ^ a b c d e "Omalizumab Monograph for Professionals". Drugs.com. Archived from the original on 11 January 2020. Retrieved 8 November 2021.
- ^ "Omalizumab (Xolair) Use During Pregnancy". Drugs.com. Archived from the original on 4 December 2020. Retrieved 8 November 2021.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 285. ISBN 978-0857114105.
- ^ "Xolair Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 January 2021. Retrieved 8 November 2021.